Saturday, March 12, 2011

Fraudulent Research Resurfaces

This month marks the two year anniversary of the GAO sting that resulted in one large independent review board's demise.  And now another fraudulent research submission?  The FDA tweeted that they were made aware of a fictitious protocol involving a multicenter, randomized, placebo-controlled study of a drug for the treatment of recurrent or neoplastic polyps.  And to make matters worse, some of the information contained in the submission appeared to have come from the GAO investigation.  You can check out the following link provided by the FDA.

No comments:

Post a Comment